Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) inhibit the proliferation of K562 (human erythromyeloblastoid leukaemic cell line)

Cell Biology International
Malini FonsekaHeng Fong Seow

Abstract

hUCB-MSC (human umbilical cord blood-derived mesenchymal stem cells) offer an attractive alternative to bone marrow-derived MSC for cell-based therapy by being less invasive a source of biological material. We have evaluated the effect of hUCB-MSC on the proliferation of K562 (an erythromyeloblastoid cell line) and the cytokine secretion pattern of hUCB-MSC. Co-culturing of hUCB-MSC and K562 resulted in inhibition of proliferation of K562 in a dose-dependent manner. However, the anti-proliferative effect was reduced in transwells, suggesting the importance of direct cell-to-cell contact. hUCB-MSC inhibited proliferation of K562, arresting them in the G0 /G1 phase. NO (nitric oxide) was not involved in the hUCB-MSC-mediated tumour suppression. The presence of IL-6 (interleukin 6) and IL-8 were obvious in the hUCB-MSC conditioned media, but no significant increase was found in 29 other cytokines. Th1 cytokines, IFNα (interferon α), Th2 cytokine IL-4 and Th17 cytokine, IL-17 were not secreted by hUCB-MSC. There was an increase in the number of hUCB-MSC expressing the latent membrane-bound form of TGFβ1 co-cultured with K562. The anti-proliferative effect of hUCB-MSC was due to arrest of the growth of K562 in the G0 /G1 phase. The ...Continue Reading

References

Oct 15, 1976·International Journal of Cancer. Journal International Du Cancer·E KleinF Vánky
Jan 1, 1994·Annual Review of Biochemistry·D S Bredt, S H Snyder
Aug 1, 1997·Progress in Neurobiology·R A Gadient, U H Otten
Jun 5, 1999·Cellular and Molecular Life Sciences : CMLS·G J MaestroniP Galli
Dec 28, 1999·Microbes and Infection·N Khalil
Jun 10, 2000·British Journal of Haematology·A EricesJ J Minguell
Nov 1, 2000·Arthritis Research·N J ZvaiflerR N Maini
Sep 27, 2001·Journal of Cellular Physiology·S GronthosJ M Gimble
Oct 5, 2001·Nature Genetics·R DerynckA Balmain
Jun 22, 2002·Nature·Yuehua JiangCatherine M Verfaillie
Jul 10, 2003·Cytokine·Henry J KlassenMonique A Berman
Jun 23, 2004·The Journal of Biological Chemistry·Geoffrey D Young, Joanne E Murphy-Ullrich
Oct 21, 2004·Blood·Sudeepta Aggarwal, Mark F Pittenger
Aug 16, 2005·Stem Cells·Panagiota A SotiropoulouMichael Papamichail
Oct 11, 2005·Experimental and Molecular Pathology·Wei ZhuYongchang Chen
Dec 27, 2005·Cytokine·Chi-Hsien Liu, Shiaw-Min Hwang
Apr 26, 2006·The Journal of Experimental Medicine·Aarif Y KhakooToren Finkel
Apr 3, 2007·Trends in Immunology·Antonio UccelliLorenzo Moretta
Apr 5, 2008·Stem Cells·Gwendal Lazennec, Christian Jorgensen
Sep 8, 2009·American Journal of Physiology. Lung Cellular and Molecular Physiology·Keith D SalazarArnold R Brody

❮ Previous
Next ❯

Citations

Nov 23, 2013·Journal of Cellular Biochemistry·Chui-Yee FongAriff Bongso
Jun 30, 2016·International Journal of Molecular Sciences·Lisa PleyerRichard Greil
Oct 27, 2017·Oncotarget·Billy Samuel HillAntonella Zannetti
Apr 27, 2019·Reviews in the Neurosciences·Ahmad MehdipourAbbas Ebrahimi-Kalan
Jul 3, 2021·Journal of Clinical Medicine·Suncica Kapor, Juan F Santibanez

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.